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Abstract
Background:  BACH1 (BRCA1-associated C-terminal helicase 1; also known as BRCA1-
interacting protein 1, BRIP1) is a helicase protein that interacts in vivo with BRCA1, the protein
product of one of the major genes for hereditary predisposition to breast cancer. Previously, two
BACH1 germ line missense mutations have been identified in early-onset breast cancer patients with
and without family history of breast and ovarian cancer.
In this study, we aimed to evaluate whether there are BACH1 genetic variants that contribute to
breast cancer risk in Finland.
Methods: The BACH1 gene was screened for germ line alterations among probands from 43
Finnish BRCA1/2 negative breast cancer families. Recently, one of the observed common variants,
Ser-allele of the Ser919Pro polymorphism, was suggested to associate with an increased breast
cancer risk, and was here evaluated in an independent, large series of 888 unselected breast cancer
patients and in 736 healthy controls.
Results: Six BACH1 germ line alterations were observed in the mutation analysis, but none of these
were found to associate with the cancer phenotype. The Val193Ile variant that was seen in only
one family was further screened in an independent series of 346 familial breast cancer cases and
183 healthy controls, but no additional carriers were observed. Individuals with the BACH1 Ser919-
allele were not found to have an increased breast cancer risk when the Pro/Ser heterozygotes (OR
0.90; 95% CI 0.70–1.16; p = 0.427) or Ser/Ser homozygotes (OR 1.02; 95% CI 0.76–1.35; p = 0.91)
were compared to Pro/Pro homozygotes, and there was no association of the variant with any
breast tumor characteristics, age at cancer diagnosis, family history of cancer, or survival.
Conclusion: Our results suggest that the BACH1 Ser919 is not a breast cancer predisposition
allele in the Finnish study population. Together with previous studies, our results also indicate that
although some rare germ line variants in BACH1 may contribute to breast cancer development, the
contribution of BACH1 germline alterations to familial breast cancer seems marginal.
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Background
BACH1 (BRCA1-associated C-terminal helicase 1, also
known as BRCA1-interacting protein 1, BRIP1; GenBank:
NM_032043) belongs to a DEAH helicase family and
interacts in vivo with BRCA1, the protein product of one of
the two major genes for hereditary breast cancer suscepti-
bility [1,2]. Interaction is mediated through BRCT
domains of BRCA1, motifs that have been shown to be
important for the ability of BRCA1 to mediate double-
strand break repair and homologous recombination as
well as transcription activation [3,4]. The BACH1 gene is
located at chromosome region 17q23. Besides genes
known to be involved in the development and progres-
sion of breast cancer, such as BRCA1 at 17q21 and ERBB2
at 17q12, the presence of other breast cancer associated
genes, both tumor suppressors and oncogenes, have been
proposed in the long arm of chromosome 17 on the basis
of loss of heterozygosity, allelic imbalance, and compara-
tive genomic hybridization studies [5-9]. The possibility
of a tumor suppressor gene located distal to BRCA1 and
involved in both sporadic and hereditary ovarian cancer
has also been discussed [10-12].
Previously, Cantor and co-workers have reported on
BACH1  germ line missense mutations in early-onset
breast cancer patients, with one of the patients having a
strong family history of both breast and ovarian cancer
[2]. In subsequent functional analysis both of the
observed mutations, Pro47Ala that is located in a highly
conserved nucleotide binding domain and Met299Ile that
resides in a helicase homology region, were shown to per-
turb BACH1 protein function by altering both ATPase and
helicase activity [13]. In addition to these rare mutations
in individual families, a common Ser-allele of the
Ser919Pro polymorphism has recently been associated
with an increased breast cancer risk; in a kin-cohort study
a 4.5-fold and up to 6.9-fold increased cumulative breast
cancer risk was seen for the first degree relatives of Pro/Ser
and Ser/Ser carriers vs. Pro/Pro carriers, respectively, by
the age of 50 years [14].
Interestingly, biallelic inactivation of BACH1 was recently
observed in patients with Fanconi Anemia (FA), a reces-
sive chromosomal instability disorder characterized by
developmental abnormalities, growth retardation, bone
marrow failure, and early predisposition to cancer
[15,16]. BACH1 mutations were observed in patients with
FA complementation group J, whereas similar inactiva-
tion of BRCA2 has been previously observed in patients
with FA complementation group D1 [17]. As individuals
with a heterozygous BRCA2 mutation are known to have
a markedly elevated risk for developing breast cancer, it's
tempting to speculate that a similar effect could also be
seen with BACH1. In epidemiological studies an excess of
breast cancer cases, although statistically non-significant,
have been observed among FA heterozygotes [18]. How-
ever, this observation needs to be taken cautiously due to
the small sample size and lack of analyses of individual
complementation groups.
In this study, we aimed to evaluate whether there are
BACH1 genetic variants that contribute to breast cancer
risk by screening the BACH1 gene for germ line alterations
among 43 Finnish BRCA1/2 negative breast cancer fami-
lies. We also evaluated the Ser919Pro variant in a large,
independent series of 888 unselected breast cancer
patients and in 736 healthy controls.
Methods
Breast cancer patients and healthy controls
Breast cancer patients belonging to 43 breast cancer fami-
lies with at least three breast or ovarian cancer cases in 1st
or 2nd degree relatives and with no detectable BRCA1/2
mutations were included in the initial mutation analysis.
Recruitment of the families through the Department of
Oncology, Helsinki University Central Hospital, Finland
as well as verification of the cancer diagnoses and exclu-
sion of the BRCA1 and BRCA2 mutations have been pre-
viously described [19-21].
The BACH1 variant Ser919Pro was analyzed in a large
series of unselected breast cancer patients and healthy
controls. The 888 unselected breast cancer patients were
collected at the Helsinki University Central Hospital, Fin-
land, during April 1997-March 1998 [22] and January-
June 2000 [23], and cover 79% of all consecutive, newly
diagnosed breast cancer cases during the collection
period. DNA samples from altogether 736 healthy
females collected at the same geographical region of
Southern Finland were studied as healthy population con-
trols. As the variant was associated with an increased
breast cancer risk by the age of 50 years [14] the study
cohort as well as the population controls were sub-
grouped according to the menopausal status (age 50 years
was chosen as a surrogate for menopause, and patients
with cancer diagnosis at < 50 years were considered pre-
menopausal and ≥50 years as postmenopausal). Breast
tumor characteristics (tumor histology, size, and grade;
nodal and distal metastasis; estrogen and progesterone
receptor status) were available from all patients. Addition-
ally, a Val193Ile variant that was found in only one family
in the initial mutation analysis was further genotyped in
randomly selected series of 346 familial breast cancer
patients and in 183 healthy population controls. All
mutation analyses have been performed on DNA samples
extracted from peripheral blood.
The study was performed with informed consent from the
patients and under appropriate research permissions from
the Ethics Committees of the Departments of ObstetricsBMC Cancer 2006, 6:19 http://www.biomedcentral.com/1471-2407/6/19
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Table 1: Primers and PCR conditions used in BACH1 mutation analysis.




2 Forward Ex2F CTGTTTCCAGATTTCTCCC
Reverse Ex2R GTGAACCCAGAAAATATTCTCC 331 58
3 Forward Ex3F CCCTGGAGTGCAATCTCACT
Reverse Ex3RN TAGCGACAGCATGGCTGAA 319 48
4 Forward Ex4F CCTGGGTGAACTGGGCTGTAG
Reverse Ex4RN TAACAGTAATAATTAAGACTC 316 48
5 Forward Ex5FN TTGCCTACCTGTAAGTTATTTATG
Reverse Ex5RN ACCATGTTCAGCTGTAACTAACTG 233 60
6 Forward Ex6F GAGCTGTTTTGGCCTTTGAGA
Reverse Ex6RN CTGAGTGGGTTGCTACTGTCCT 317 55
7 Forward Ex7F GTTCTGATTCCATGTGAGGTT
Reverse Ex7R GTACATATAAAACACATACTGAGT 448 55
8 Forward Ex8F GATGTTCCTCAAATTCTGAGATAA
Reverse Ex8R CATCTAAAAGCTTTTACATTCAAC 386 55
9 Forward Ex9F GCCTATAGTGTGAATTTTAAAATG
Reverse Ex9R CCTAGTTAACCAAAGTTTACTAAC 395 55
10 Forward Ex10F GATCAACGCATGACAATAATGATG
Reverse Ex10R GGGTTACTCACTAGATTTAATCTG 320 55
11 Forward Ex11F GCATGTTTTGTTGGGTTTCATTGT
Reverse Ex11R GGTATGTATTAAACACATGCTAGC 326 55
12 Forward Ex12F GTACCAGCTCTTTCAAATGAG
Reverse Ex12R CTATCTTTAAAAGAGTCAACCAC 360 55
13 Forward Ex13FN GTGCTGGGATTACAGGTGTGAGCCA
Reverse Ex13RN ACTTGCTGGCACTTCAGGTATCTTC 317 60
14 Forward Ex14F CTTGTTGCTTGATCTTTTATGTAC
Reverse Ex14R CTAGGAAGCTTACTGTGGTAA 356 55
15 Forward Ex15FN ACAGCTCTATGAGATATATTG
Reverse Ex15RN TCATAGGAGAACAAGTACAAT 504 55
16 Forward Ex16FN TTACTTAAAGACATTGAACTT
Reverse Ex16RNN CACTATAAAAGCAAAGCGC 392 54
17 Forward Ex17FN CTGTTAGAAGTTAATATGATG
Reverse Ex17RN GAATACATACCAGTTCCTATG 325 55
18 Forward Ex18F CCAATTTTCTGTCTGTCCCAC
Reverse Ex18R GATAGTAGAGCTCATGTTATGTG 254 55
19 Forward Ex19F CTTCACTAGAAAAAGCAAGTG
Reverse Ex19R CCACCATATTTAAGGAATTAATC 523 48
20A Forward Ex20AFN ACCTAGCAATTATGTTAGCT
Reverse Ex20ARN TCTGTATCTTCAGGATCGTA 584 48
20B Forward Ex20BFN ATTGATGCCACCCTTACTA
Reverse Ex20BRNN TAACATAAGCATGATGACATA 565 54
and Gynecology, and Oncology, Helsinki University Cen-
tral Hospital, Finland, as well as Ministry of Social Affairs
and Health in Finland.
Mutation analysis
The coding region and exon-intron boundaries of BACH1
were screened using conformation sensitive gel electro-
phoresis (CSGE) with modifications previously described
[24]. Samples with aberrant CSGE profiles were reampli-
fied, and the nucleotide changes determined by direct
sequencing. Primers and PCR conditions used in the
mutation analysis are presented in table 1. The frequency
of the Ser919Pro alteration was determined by Amplif-
luor™ fluorescent genotyping (K-Biosciences, Cambridge,
UK). The genotyping for nt c.2755 (codon 919) was suc-
cessful in 866/888 (97.5%) breast cancer patient samples
and in 731/736 (99.3%) healthy control samples. The
Val193Ile (c.577G>A) variant was genotyped in 346 (suc-
cessful in 336, 97.1%) familial breast cancer samples and
in 183 (successful in 167, 91.3%) control samples, respec-
tively, by Amplifluor™ fluorescent genotyping as well.
Statistical analysis
Possible associations between the BACH1 Ser919Pro and
breast cancer risk, as well as the variant and clinico-path-
ologic features of the tumors, were tested by univariate
analysis. Independent variables were compared with the
chi-square test. The mean age at breast cancer diagnosesBMC Cancer 2006, 6:19 http://www.biomedcentral.com/1471-2407/6/19
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between the carriers and non-carriers was compared by
one-way ANOVA. All p-values were 2-sided, and p-value <
0.01 was considered statistically significant as suggested
by Houlston and Peto [25]. All statistical analyses were
carried out in the SPSS software (version 12.0 for Win-
dows, SPSS, Chicago, IL, USA).
Results and discussion
Altogether six germ line BACH1 variants were observed in
the initial mutation analysis (Table 2). Four of the
changes were in the coding region, two of these were mis-
sense and two silent substitutions. The missense changes
were analyzed further for their possible association with
breast cancer risk. The silent alterations have been sug-
gested as neutral polymorphisms by the previous studies
[2,26,27], and were not studied here further. The one mis-
sense substitution, Val193Ile, was seen in only one family.
In addition to the proband diagnosed with breast cancer
at the age of 54 years, the variant was also seen in her
healthy father and healthy brother, father's sister diag-
nosed with skin cancer at age 85 years, and the aunts' three
children diagnosed with breast cancer at 63 years, ovarian
cancer at 59 years, and skin cancer at 64 years, respec-
tively. The grandmother of the proband, whose carrier sta-
tus is unknown, has been diagnosed with breast cancer at
age 74 years. The variant was not observed among 336
familial breast cancer patients or in 167 healthy popula-
tion controls. It has previously been observed in 3/200
(1.5%) healthy controls and classified as a rare polymor-
phism [2]. The residue resides in close proximity to the
ATP/GTP binding site, and the possible functional signif-
icance of this rare variant to BACH1 protein function
remains to be determined.
Table 3: Genotypes of the BACH1 Ser919Pro variant among 866 unselected breast cancer patients and 731 healthy population 
controls.
Cases Controls
n%n% O R * 9 5 %  C I p
Unselected breast cancer patients, all 866 731
Pro/Pro 184 21.2 148 20.2 1
Pro/Ser 428 49.4 382 52.3 0.901 0.697–1.165 0.427
Ser/Ser 254 29.3 201 27.5 1.016 0.765–1.351 0.911
Pro/Ser + Ser/Ser 682 78.8 583 79.8 0.941 0.738–1.120 0.623
Unselected breast cancer patients, diagnosis <50 years 276 476
Pro/Pro 56 20.3 96 20.2 1
Pro/Ser 140 50.7 249 52.3 0.964 0.653–1.423 0.853
Ser/Ser 80 29 131 27.5 1.047 0.680–1.611 0.835
Pro/Ser + Ser/Ser 220 79.7 380 79.8 0.993 0.686–1.436 0.968
Unselected breast cancer patients, diagnosis ≥50 years 590 255
Pro/Pro 128 21.7 52 20.4 1
Pro/Ser 288 48.8 133 52.2 0.878 0.600–1.289 0.511
Ser/Ser 174 29.5 70 27.5 1.010 0.660–1.545 0.964
Pro/Ser + Ser/Ser 462 78.3 203 79.6 0.925 0.644–1.328 0.671
* as compared to Pro/Pro homozygotes
Table 2: Observed germ line variants in BACH1.
Exon/Intron Nucleotide change Amino acid change Frequency for heterozygotes 
(%)
int5 508-31 C→G - 11/43 (25.6)
ex6 577 G→A Val193Ile 1/43 (2.3)
int14 2097+7 G→A - 1/43 (2.3)
ex19 2637 G→A Glu879Glu 31/43 (72.1)*
ex19 2755 C→T Ser919Pro 32/43 (74.4)*
ex20 3411 C→T Tyr1137Tyr 27/43 (62.8)*
* also homozygotes for the rare alleleBMC Cancer 2006, 6:19 http://www.biomedcentral.com/1471-2407/6/19
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The other observed missense substitution, a common pol-
ymorphism Ser919Pro, was associated with an elevated
breast cancer risk during the course of this study [14]. In
that study the relative cumulative risk by the age 50 years
was 4.5 for the female first degree relatives of Pro/Ser het-
erozygotes (95% CI 0.8–12.2; p = 0.096) and up to 6.9
(95% CI 1.6–29.3; p = 0.018) for the first degree relatives
of Ser/Ser homozygotes, when compared to Pro/Pro
homozygotes. However, no significant association was
seen when the analysis was extended to age 70 years (OR
1.3, 95%CI 0.8–2.8, p = 0.220) [14]. Here we found no
association of the variant with breast cancer risk. The odds
ratios for the whole study cohort as well as for the pre- and
postmenopausal patient groups were close to one both for
the Pro/Ser heterozygotes and for the Ser/Ser homozy-
gotes when compared to Pro/Pro homozygotes (Table 3).
The alteration did not associate with breast cancer family
history (data not shown). No association of the variant
with any of the breast tumor characteristics (Table 4) or
survival (data not shown) was seen either, and also the
age at breast cancer diagnosis was similar in all genotype
carrier groups (56.9 years for the Pro/Pro homozygotes,
56.8 years for the heterozygotes, and 56.1 years for the
Ser/Ser homozygotes, respectively; p = 0.705). Our data
suggest that the BACH1  Ser919Pro alteration is not a
breast cancer predisposition allele in our study popula-
tion although a very low risk effect cannot be excluded. A
joint effect on breast cancer risk by the Ser919Pro variant
and other epidemiological risk factors may also be possi-
ble.
Our data, together with previous studies, suggest that
germ line mutations in BACH1 do not substantially con-
tribute to the remaining proportion of the familial aggre-
gation of breast cancer outside the high-penetrance genes
BRCA1  and  BRCA2  [2,26-28]. In the future, it will be
interesting to see whether the heterozygous BACH1 muta-
tion carriers in FA families have an excess risk of develop-
ing breast or other type of cancer. So far, heterozygous
mutations of the FA genes, with the exception of BRCA2,
Table 4: Tumor characteristics of the 909 breast tumors from 866 breast cancer patientsanalyzed for the BACH1 Ser919Pro variant.
BACH1 Ser919Pro
Total n (%) Pro/Pro Pro/Ser Ser/Ser p
Histology 909
Carcinoma ductale 713 (78.4) 145 (76.3) 358 (78.7) 210 (79.5) 0.480
Carcinoma lobulare 130 (14.3) 25 (13.2) 70 (15.4) 35 (13.3)
Carcinoma medullare 13 (1.4) 5  ( 2 . 6 )5  ( 1 . 1 )3  ( 1 . 1 )
Other 53 (5.8) 15 (7.9) 22 (4.8) 16 (6.1)
Tumor grade 817
1 223 (27.3) 51 (29.8) 116 (28.2) 56 (23.9) 0.702
2 353 (43.2) 73 (42.7) 174 (42.2) 106 (45.3)
3 241 (29.5) 47 (27.5) 122 (29.6) 72 (30.8)
Tumor size, pT 887
1 545 (61.4) 121 (65.8) 269 (60.7) 155 (59.6) 0.423
2 282 (31.8) 47 (25.5) 148 (33.4) 87 (33.5)
3 31 (3.5) 7 (3.8) 15 (3.4) 9 (3.5)
4 29 (3.3) 9 (4.9) 11 (2.5) 9 (3.5)
Lymph node status, pN 909
Negative 477 (52.5) 104 (54.7) 223 (49.0) 150 (56.8) 0.101
Positive 432 (47.5) 86 (45.3) 232 (51.0) 114 (43.2)
Distant Metastasis, pM 870
Negative 829 (95.3) 168 (93.9) 416 (96.1) 245 (95.0) 0.478
Positive 41 (4.7) 11 (6.1) 17 (3.9) 13 (5.0)
Estrogen receptor status 862
Positive 680 (78.9) 139 (76.8) 339 (78.5) 202 (81.1) 0.530
Negative 182 (21.1) 42 (23.2) 93 (21.5) 47 (18.9)
Pogesterone receptor status 863
Positive 591 (68.5) 129 (70.9) 289 (66.9) 173 (69.5) 0.577
Negative 272 (31.5) 53 (29.1) 143 (33.1) 76 (30.5)BMC Cancer 2006, 6:19 http://www.biomedcentral.com/1471-2407/6/19
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have been found to be extremely rare, or nonexistent, in
breast cancer families [29], and the studied polymor-
phisms have not been found to confer an increased risk
for breast cancer [[30], this study].
Conclusion
Taken together, our results are in concordance with previ-
ous studies where germ line BACH1 mutations have been
observed in only a very few familial breast cancer patients
[2,26-28]. This suggests that even though some function-
ally deleterious germ line BACH1 mutations have been
observed in breast cancer patients, such mutations are rare
and may account for only a very small proportion, if any,
of non-BRCA1/2 familial breast cancer. Our results further
indicate that BACH1 Ser919 is not a breast cancer predis-
position allele in the Finnish population.
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